1. "2020"
Formats
  1. Journal Article (2337)
  2. Meeting Abstract (1901)
  3. Review (493)
  4. Editorial (342)
  5. Correspondence (121)
  6. Guidelines (114)
  7. Book Section (99)
  8. Research Letter (95)
  9. Miscellaneous (61)
  10. Conference Paper (33)
  11. Book Whole (2)
Groups
  1. Department of Medicine (2560)
  2. Solid Tumor Oncology Division (1535)
  3. GSK Faculty (1257)
  4. Sloan Kettering Institute Postdocs (1240)
  5. Hematologic Malignancies, Division of (936)
  6. Survivorship Research (930)

More Groups

People
  1. Jorge Reis-Filho (93)
  2. Miguel-Angel Perales (93)
  3. Sergio Giralt (91)
  4. Alexander Drilon (81)
  5. Britta Weigelt (76)
  6. Nadeem Abu-Rustum (71)

More People

Years
  1. 2020 (5598)
Publications
  1. Journal of Clinical Oncology (500)
  2. Blood (212)
  3. Cancer Research (185)
  4. Annals of Oncology (152)
  5. International Journal of Radiation Oncology, Biology, Physics (129)
  6. Laboratory Investigation (116)

More Publications

Publishers
  1. Elsevier Inc. (714)
  2. American Society of Clinical Oncology (548)
  3. Nature Publishing Group (385)
  4. American Association for Cancer Research (357)
  5. Oxford University Press (356)
  6. Springer (342)

More Publishers

Results (5598)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors
    Meeting Abstract

    O'Donnell, P.; Galsky, M. D.; Rosenberg, J. E.; Petrylak, D. P.; Balar, A. V.; McGregor, B. A.; Heath, E.; Yu, E. Y.; Quinn, D. I.; Hahn, N. M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Association between gene expression signatures (sigs) and pembrolizumab (pembro) efficacy in patients (pts) with advanced urothelial cancer (UC)
    Meeting Abstract

    Grivas, P.; Balar, A. V.; Vuky, J.; de Wit, R.; Vogelzang, N. J.; Choueiri, T. K.; Bajorin, D.; Castellano Gauna, D.; Gerritsen, W.; Gurney, H.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Association of TMB with efficacy of pembrolizumab (pembro) in patients (pts) with advanced urothelial cancer (UC): Results from KEYNOTE-045 and KEYNOTE-052
    Meeting Abstract

    Bellmunt, J.; de Wit, R.; Fradet, Y.; Climent, M. A.; Petrylak, D. P.; Lee, J. L.; Fong, L.; Necchi, A.; Sternberg, C. N.; Grivas, P.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Nivolumab + ipilimumab (N + I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy
    Meeting Abstract

    Albiges, L.; Tannir, N.; Burotto, M.; McDermott, D. F.; Plimack, E. R.; Barthélémy, P.; Porta, C. G.; Powles, T. B.; Donskov, F.; George, S.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Correlative serum biomarker analyses: Lenvatinib (LEN) plus pembrolizumab (PEMBRO) in a phase Ib/II trial in advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Lee, C. H.; Adachi, Y.; Ikezawa, H.; Li, S. D.; Funahashi, Y.; Minoshima, Y.; Kubiak, P.; Perini, R.; Ren, M.; Smith, A. D.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Phase II trial of lenvatinib (LEN) + pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses
    Meeting Abstract

    Lee, C. H.; Shah, A. Y.; Hsieh, J. J.; Rao, A.; Pinto, A.; Bilen, M. A.; Cohn, A. L.; Di Simone, C.; Shaffer, D. R.; Girones Sarrio, R.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naive, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC)
    Meeting Abstract

    Msaouel, P.; Siefker-Radtke, A. O.; Sweis, R.; Mao, S.; Rosenberg, J. E.; Vaishampayan, U. N.; Rezazadeh Kalebasty, A.; Pili, R.; Bupathi, M.; Nordquist, L. T.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Clinical and immune responses to immunotherapy in biochemically recurrent (non-metastatic castration sensitive) prostate cancer (BCRpc)
    Meeting Abstract

    Madan, R. A.; Slovin, S.; Harshman, L. C.; Wei, X. X.; Bilusic, M.; Karzai, F. H.; Donahue, R. N.; Toney, N. J.; Strauss, J.; Cordes, L.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Rucaparib population pharmacokinetics (PPK) and exposure-response (ER) analyses in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2
    Meeting Abstract

    Chowdhury, S.; Patnaik, A.; Campbell, D.; Shapiro, J.; Bryce, A. H.; McDermott, R.; Sautois, B.; Vogelzang, N. J.; Bambury, R.; Voog, E.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Phase I first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumours
    Meeting Abstract

    Powderly, J.; Shimizu, T.; Lorusso, P.; Razak, A.; Miller, K. D.; Balar, A. V.; Bruix, J.; Michel, L. S.; Blaney, M.; Guan, X.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save